$Lexeo Therapeutics(LXEO.US)$ NEWS Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Lexeo's CEO acknowledged significant progress made in 2023, credited to the successful IPO. He anticipates more clinical data from cardiovascular and Alzheimer's disease programs in 2024.
Lexeo Therapeutics股票討論區
NEWS
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
暫無評論